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Abstract 
Human brain aging is the physiological process which underlies as cause of cognitive decline in 
the elderly and the main risk factor for neurodegenerative diseases such as Alzheimer’s disease. 
Human neurons are functional throughout a healthy adult lifespan, yet the mechanisms that 
maintain function and protect against neurodegenerative processes during aging are unknown. 
Here we show that protein oxidative and glycoxidative damage significantly increases during 
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human brain aging, with a breakpoint at 60 years old. This trajectory is coincident with a decrease 
in the content of the mitochondrial respiratory chain complex I to IV. We suggest that the 
deterioration in oxidative stress homeostasis during aging induces an adaptive response of stress 
resistance mechanisms based on the sustained expression of REST, and increased or decreased 
expression of Akt and mTOR, respectively, over the adult lifespan in order to preserve cell neural 
survival and function. 
 
Keywords: cell survival pathways, mechanistic target of rapamycin (mTOR), mitochondria 
respiratory chain, mitochondrial stress, protein oxidation, repressor element 1-silencing 
transcription factor (REST) 
 
 
 
Introduction 
Human brain aging is a process characterized by structural and physiological changes at all levels 
of the biological organization leading to cognitive functional losses [1–4]. Indeed cognitive 
decline is becoming a health challenge of the present century. This challenge is consequence of 
the increase in life expectancy of the population, origin of the increase in the prevalence of 
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cognitive decline and dementia, mostly in the form of Alzheimer’s disease (AD). Thus, current 
data indicate that eighty-one percent of people who have AD are age 75 or older in the United 
States [5]. So, the main cause and risk factor for cognitive decline and AD in the elderly is age 
itself. Functional genetic analysis has identified signaling pathways and phenotypes that influence 
aging in model organisms and brain aging in mammals. Among them, of particular note are 
changes in genes involved in both mitochondrial and synaptic function [2,3,6–13]. 
Human neurons, however, are functional throughout an entire healthy adult lifespan, in contrast 
to AD pathology or other neurodegenerative diseases, but the mechanisms that maintain function 
and protect against neurodegeneration during aging are unknown. Available evidence suggest that 
oxidative stress is a conserved mechanism of age-related functional decline [13,14], but 
surprisingly little is known about the changes occurring in oxidative damage in the human brain 
over the adult lifespan. Furthermore, the methods used in these studies did not allow 
measurement of specific markers and their trajectories during aging, and any changes at this level 
are yet to be determined.   
In the present work, the use of mass spectrometry technologies allowed us to determine a 
specific non-enzymatic oxidative protein damage profile of the human frontal cortex in 
individuals ranging from 40 to 90 years old. The choice of frontal cortex is based on the fact that 
it is a brain region that emerged recently during primate evolution and it is implicated in cognitive 
function including reasoning, planning, social behavior, and general intelligence. In addition to 
the protein damage marker analysis, we also measured the content of mitochondrial complexes of 
the electron transport chain, as well as different factors associated with stress resistance and cell 
survival such as the repressor element 1-silencing transcription factor REST, a regulator of 
neuroprotective stress response, and the serine/threonine kinase AKT, a member of the AKT 
signal transduction pathway that promotes cell survival, and the master regulator that senses cell 
nutrient and energy status, the mechanistic target of rapamycin mTOR. 
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Experimental Procedures 
Chemicals  
Unless otherwise specified, all reagents were from Sigma-Aldrich, and of the highest purity 
available. 
Human samples  
Brain samples were obtained from the Institute of Neuropathology Brain Bank following the 
guidelines of the local ethics committee, and in accordance with recently published criteria of 
sample quality [15]. The selection of cases examined in the present study corresponded to a 
consecutive series of donations having in common (i) lack of neurological symptoms and signs, 
(ii) lack of known hepatic or renal function impairment, and (iii) lack of evidence of prolonged 
agonal state. 
The neuropathological study was performed in every case as previously describe [16]. Briefly, at 
autopsy, one hemisphere was fixed in 4% buffered formalin for about three weeks while the 
other hemisphere was cut in coronal sections 1 cm thick; selected samples of the brain were 
dissected and kept in labelled plastic bags, immediately frozen on dry ice, and stored at -80°C 
until use. The neuropathological study, was carried out on formalin-fixed, paraffin-embedded 
samples of the frontal, primary motor, primary sensory, parietal, temporal superior, temporal 
inferior, anterior cingulated, anterior insular, and primary and associative visual cortices; 
entorhinal cortex and hippocampus; caudate, putamen and globus pallidus; medial and posterior 
thalamus; subthalamus; Meynert nucleus; amygdala; midbrain (two levels), pons and medulla 
oblongata; and cerebellar cortex and dentate nucleus. De-waxed sections, 5 mm thick, were 
stained with haematoxylin and eosin, and Klu  ver Barrera, or processed for 
immunohistochemistry to β-amyloid, phosphorylated tau, α-synuclein, ubiquitin, p62, TDP43, 
glial fibrillary protein, and microglia markers. 
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Selected cases did not show lesions on neuropathological examination including any kind of β-
amyloid, tau, hypoxic, or vascular pathology. Following initial screening, the present series 
included 41 cases: 22 men and 19 women, with an age ranging from 43 to 86 years, and with 
post-mortem delay ranging from 2h to 19h 30 min (Table 1).  Frozen samples of frontal cortex 
area 8 were used for biochemical studies. 
Protein oxidation, glycoxidation, and succination  
Markers of protein oxidation (the protein carbonyls glutamic [GSA] and aminoadipic [AASA] 
semialdehydes), glycoxidation (carboxyethyl-lysine [CEL], carboxymethyl-lysine [CML], and 
carboxymethyl-cysteine [CMC]), and succination (S-(2-succinyl) cysteine [2SC]), were determined 
as trifluoroacetic acid methyl ester (TFAME) derivatives in acid hydrolyzed delipidated and 
reduced tissue protein samples by gas chromatography/mass spectrometry (GC/MS) [17] using 
an HP6890 Series II gas chromatograph (Agilent, Barcelona, Spain) with an MSD5973A Series 
detector and a 7683 Series automatic injector, a HP-5MS column (30-m x 0.25-mm x 0.25-µm), 
and the described temperature program [17]. Quantification was performed by internal and 
external standardization using standard curves constructed from mixtures of deuterated and non-
deuterated standards. Analyses were carried out with selected ion-monitoring GC/MS (SIM-
GC/MS). The ions used were: lysine and [2H8]lysine, m/z 180 and 187, respectively; 5-hydroxy-2-
aminovaleric acid and [2H5]5-hydroxy-2-aminovaleric acid (stable derivatives of GSA), m/z 280 
and 285, respectively; 6-hydroxy-2-aminocaproic acid and [2H4]6-hydroxy-2-aminocaproic acid 
(stable derivatives of AASA), m/z 294 and 298, respectively; CEL and [2H4]CEL, m/z 379 and 
383, respectively; CML and [2H2]CML, m/z 392 and 394, respectively; CMC and [
13C3-
15N]CMC, 
m/z 271 and 273, respectively; and 2-SC and [2H2]SC, m/z 284 and 286. The amounts of product 
were expressed as µmoles of GSA, AASA, CEL, CML, CMC, or SC per mole of lysine. 
Western blotting  
The amounts of a) the mitochondrial respiratory chain complex I to IV, b) the complex I 
regulatory factors AIF (apoptosis-inducing factor), c) the repressor element 1-silencing 
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transcription factor REST, and d) the serine/threonine kinase AKT, a member of the AKT signal 
transduction pathway that promotes cell survival, and the master regulator that senses cell 
nutrient and energy status, the mechanistic target of rapamycin mTOR, were estimated using 
western blot analyses in samples from brain tissue as previously describe [18]. Briefly, brain 
samples (50mg) were homogenized in a buffer containing 180 mM KCl, 5 mM MOPS, 2 mM 
EDTA, 1 mM diethylenetriaminepentaacetic acid, 1 µM butylated hydroxyltoluene, protease 
inhibitor mix (80-6501-23, Amersham Biosciences), and phosphatase inhibitors (Na3VO4 1 mM, 
NaF 1mM). After a brief centrifugation (1000 rpm at 4°C for 3 min) to pellet cellular debris, 
protein concentrations were measured in the supernatants using the Bradford method (Bio-Rad 
Protein Assay 500-0006). Proteins were separated by one-dimensional SDS-PAGE. Samples were 
mixed with sample buffer (62.5 mM Tris–HCl pH 6.8, 2% SDS, 10% glycerol, 20% 2-β-
mercaptoethanol and 0.02% bromophenol blue) and heated at 95°C for 5 min. Proteins (20 μg 
for respiratory chain complexes and AIF, and 35 µg for the others) were subjected to 
electrophoresis on 10% SDS-polyacrylamide minigels. For immunodetection, proteins were 
transferred using a Mini Trans-Blot Transfer Cell (Bio Rad) in a buffer containing 25 mM TRIS, 
192 mM glycine, and 20% methanol, to polyvinylidene difluoride (PVDF) membranes 
(Immobilon-P Millipore, Bedford, MA). The membranes were immersed in blocking solution 
(0.2% I-Block Tropix AI300 or 0.5% BSA Sigma-Aldrich A4503, 0.1% Tween in TBS) at room 
temperature for 1 hour. After blocking, the membrane was washed two times using 0.05% TBS-T 
buffer. Afterwards, the membrane was incubated in primary solution using specific antibodies: 
anti-29kDa (NDUFS3) subunit of complex I (1:1000, ref. 459130, Invitrogen), anti-70kDa 
subunit (Flavoprotein) of complex II (1:500, ref. 459200, Invitrogen), anti-48kDa (CORE 2) 
subunit of complex III (1:1000, ref. 456220, Invitrogen), anti-57kDa (COXI subunit) of complex 
IV (1:1000, ref. 459600, Invitrogen), anti-AIF (1:1000, ref. A7549, Sigma), anti-porin (1:1000, ref. 
A31855, Molecular Probes), anti-actin (1:5000, ref. A5411, Sigma), anti-REST (1:1000, ref. 
ab21635, Abcam), anti-phospho-Akt (1:1000, ref. 9271, Invitrogen) and anti-Akt (1:1000, ref. 44-
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609G, Invitrogen), and anti-phospho-mTOR and anti-mTOR (1:1000 in both cases, ref. 2971s 
and 2972-Cell Signaling Technology, respectively).  
The primary antibody was incubated at room temperature for 1 hour for mtComplexes and AIF, 
and at 4°C for 16 h for the other factors.  The membrane was washed three times in 0.05% TBS-
T buffer and incubated at room temperature for 1 hour with the appropriate secondary 
antibodies [ECL Anti-mouse IgG, horseradish Peroxidase linked whole antibody-NA93IV GE 
Healthcare (1:30000) and ImmunoPure Goat Anti-Rabbit IgG peroxidase conjugated-31460 
Pierce Biotechnology (1:100000)]. After five washes with 0.05% TBS-T buffer, bands were 
visualized using an enhanced chemiluminescence HRP substrate (Millipore, MA, USA). Signal 
quantification and recording was performed with ChemiDoc equipment (Bio-Rad Laboratories, 
Inc., Barcelona, Spain). The amounts of the determined factors were specifically calculated from 
the ratio of their densitometry values in reference to the densitometry values of their own porin 
content. The amount of REST was specifically calculated from the ratio of their densitometry 
values in reference to the actin content. Ratios of phospho-mTOR to total-mTOR, and phospho-
AKT to total-AKT, were also calculated. 
RNA purification, retrotranscription reaction, and TaqMan PCR 
RNA purification, retrotranscription reaction and taqman PCR were performed as previously 
described [19]. Briefly, the purification of RNA from human frontal cortex (n = 3-4 samples per 
decade) was carried out with RNeasy Lipid Tissue Mini Kit (Qiagen, Hilden, Germany) following 
the protocol provided by the manufacturer, after DNase digest to avoid extraction and later 
amplification of 
genomic DNA. Quality of isolated RNA was first measured with Bioanalyzer Assay (Agilent, 
Santa Clara, CA). The concentration of each sample was obtained from A260 measurements with 
Nanodrop 2000 (Thermo Scientific, Wilmington, DE). RNA integrity (RIN) was tested using the 
Agilent 2100 BioAnalyzer (Agilent Technologies, Palo Alto, CA). RIN values were higher than 6 
for all samples used (see Table 1). 
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The retrotranscriptase reaction was carried out using a High-Capacity cDNA Archive kit 
(Applied Biosystems, Foster City, CA) following the protocol provided by the supplier. Parallel 
reactions for an RNA sample were run in the absence of MultiScribe Reverse Transcriptase to 
assess the degree of contaminating genomic DNA. 
TaqMan quantitative RT-PCR assays for each gene were performed in triplicate on cDNA 
samples obtained from the retrotranscription reaction using the ABI Prism 7900 Sequence 
Detection system (Applied Biosystems, Life Technologies, Waltham, MA). For each 10μL 
TaqMan reaction, 4.5μL cDNA was mixed with 0.5μL 20x TaqMan Gene Expression Assays and 
5μL of 2x TaqMan Universal PCR Master Mix (Applied Biosystems). The reactions were carried 
out using the following parameters: 50°C for 2min, 95°C for 10 min, and 40 cycles of 95°C for 
15 seconds and 60°C for 1min. Finally, all TaqMan PCR data were captured using the Sequence 
Detection Software (SDS version 1.9; Applied Biosystems). The identification numbers and 
names of all TaqMan probes used are shown in Supporting Information Table S1. Samples were 
analyzed with the double-delta cycle threshold (ΔΔCT) method. The ΔCT values represent 
normalized target gene levels with respect to the internal control (ACTB). The ΔΔCT values were 
calculated as the ΔCT of each test sample minus the mean ΔCT of the calibrator samples for 
each target gene. The fold change was determined using the equation 2(−ΔΔCT). 
Immunohistochemistry 
Tissue immunohistochemistry was made as previously described [19]. Briefly, Tissue samples 
were embedded in paraffin, and 4-μm thick coronal sections were obtained with a sliding 
microtome. Endogenous peroxidases were blocked by incubation in 10% methanol–1% H2O2 
solution for 15 minutes, followed by 3% normal horse serum solution, and then incubated at 4°C 
overnight with one of the primary antibodies indicated-that is, anti-mtComplex 1 (ref. 459130, 
Invitrogen), anti-REST (ref. ab21635, Abcam), anti-Akt (ref. 44-609G, Invitrogen), and anti-
mTOR (ref. 2972-Cell Signaling Technology).  Sections were subsequently rinsed and incubated 
with biotinylated secondary antibody (Dako, Glostrup, Denmark), followed by EnVision+ 
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system peroxidase (Dako) and, finally, the chromogen diaminobenzidine and H2O2. Some 
sections were incubated without the primary antibodies; no immunostaining was detected in 
these sections. Sections were lightly counterstained with hematoxylin. After staining, the sections 
were dehydrated and coverslipped for microscopic assessment. The mounting medium used for 
image acquisition was DPX. Images were acquired with an Olympus BX51 microscope (UPlan 
FL N 20 × /0.50 Ph1) (Olympus Corporation, Tokyo, Japan) connected to an Olympus DP71 
camera and Cell^B software (Olympus Corporation). 
Statistics   
To model the relationships between brain age and protein oxidative damage biomarkers were 
used, both generalized additive model (GAM) and joinpoint regression. GAM [20] is an 
extension of the Generalized Linear Model (GLM) where the assumption of linear dependency 
between the response variable and the covariates is relaxed. GAMs provide more flexibility than 
GLMs to capture non-linear relationships by using smooth functions like piecewise polynomials 
that join at points called knots. After the GAM analysis, in order to search for a potential break 
point in the age variable in relation to each independent variable (protein oxidative damage 
biomarkers) a joinpoint regression was applied. Joinpoint regression is a statistical modeling 
technique that explains the relationship between two variables by means of a segmented linear 
regression constrained so as to be continuous everywhere, in particular in those places where the 
slope of the regression function changes. These two analyses were done using the libraries 
“mgcv” and “segmented” of the R statistical software v.2.10.  
Regression equations were obtained using nonlinear regression analyses with the curve estimation 
method of the SPSS/PC software for Windows (SPSS, Chicago, IL). Comparisons between 
groups were analyzed with one way ANOVA. These statistical analyses were performed using the 
SPSS software (SPSS, Chicago, IL, USA). The level of statistical significance was set at p<0.05 in 
all the analyses.  
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Results 
Comparative studies of gene expression and evolution suggest that neurons from human 
neocortex are characterized by high levels of energy metabolism [21,22]. Furthermore, available 
evidence suggest that progressive oxidative damage, mitochondrial dysfunction, and defects of 
energy metabolism are mechanisms of age-related functional decline of the human brain [13]. We 
applied this idea to a key region of the adult human brain, the frontal cortex, to evaluate temporal 
trajectories of specific protein damage markers using a mass spectrometry technique, as direct 
markers of protein oxidation. Our results demonstrate the existence of a significant relationship 
between frontal cortex specific protein damage markers and age analysed by generalized additive 
model (GAM). In particular, this relationship shows an increase with age for the protein 
oxidation-derived markers GSA and AASA, and the glycoxidation-derived markers CEL and 
CML (p-values of the age smooth term were p <0.00001 for GSA and AASA, p=0.0003 for 
CEL, and p=0.012 for CML) (Figure 1). 
Protein cysteine residues can suffer post-translational modifications by oxidation, S-
glutathionylation, S-nitrosylation, glycoxidation, and succination reactions, all of which modify 
protein structure and function in response to a changing intracellular redox environment [23]. In 
particular, succination is a nonenzymatic chemical modification of cysteine in proteins by the 
Krebs cycle metabolite, fumarate, yielding 2-SC. 2-SC serves as a biomarker of mitochondrial 
stress [24]. In contrast to oxidative and glyoxidative markers, no changes associated with age for 
the protein non-enzymatic modification of the cysteine residues CMC and the cysteine-derived 
succination marker SC were detected. (p-values of the age smooth term were p=0.114 for CMC, 
and p=0.155 for 2-SC) (Figure 1). 
Reinforcing our findings, the potential interference of the variables gender and post-mortem time 
in the temporal trajectories of the different protein damage markers was ruled out after applying 
the corresponding GAM analysis (see Supporting Information). 
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To shed light upon a possible juncture when brain aging begins, we applied a jointpoint 
regression model to determine the breakpoint where the temporal trajectories for oxidative and 
glycoxidative markers show a significant inflection point followed with a more pronounced 
increase in protein damage. Our analysis suggests that the breakpoint is located around 60 years 
old (GSA: 62.64 ± 6.79 years old, R2(adj)=0.5459; AASA: 63.77 ± 5.64 years old, R2(adj)=0.538; 
CEL: 63.60 ± 20.44 years old, R2(adj)=0.2868). 
Because studies of brain aging has demonstrated a progressive decline in mitochondrial gene 
expression in different animal species such as rats, rhesus macaques, and humans [8,9,25], and 
mitochondrial function is involved in the aging process [26], we investigated the content of 
mitochondrial electron transport chain complexes during human brain aging. Our results showed 
a significant decrease in the concentration of all electron transport chain complexes (from CI to 
CIV) with age, with this trajectory especially evident in the decade following age 50 for CI and 
age 60 for CII, CIII, and CIV (Figure 2). In parallel, we also observed a decrease in the content 
of mitochondrial AIF which is consistent with the decrease in the amount of complex I because 
AIF, in addition to their apoptotic properties, has a specific role in the biogenesis and 
maintenance of complex I [27,28] (Figure 2). In contrast, the expression of complex V (ATP 
synthase) did not show any difference with age. 
We then considered whether these changes in protein oxidative damage and mitochondrial 
complexes might be associated with changes/adaptions in cellular systems linked to stress 
resistance and cell survival. To this end, we measured the repressor element 1-silencing 
transcription factor REST, a regulator of neuroprotective stress response [29], and the 
serine/threonine kinase Akt, a member of the Akt signal transduction pathway that promotes cell 
survival, and the master regulator that senses cell nutrient and energy status, the mechanistic 
target of rapamycin mTOR [30]. Western blot analysis showed sustained expression of REST 
over the adult lifespan which was also observed for mRNA expression (Figure 3). Interestingly, a 
significant correlation was also observed, expressed through a quadratic equation, between the 
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REST content and the protein oxidation markers GSA and AASA (Figure 4). The protein 
expression of Akt increased significantly with age, especially at advanced ages, but this is not 
reflected in the mRNA levels, whereas mTOR protein expression and mRNA levels decrease 
significantly with age from the 60 years old (Figure 3).  
In this line, the results obtained with immunohistochemistry for complex I, REST, Akt, and 
mTOR in human frontal cortex tissue confirm the temporal trajectories described above and 
demonstrate that the observed changes may be ascribed to neurons (Figure 5). Thus, the punctate 
cytoplasmic Complex I immunoreactivity detected in neurons, suggestive of their mitochondrial 
location, showed a decrease in staining across the decades. For REST, nuclear immunoreactivity 
was detected in neurons which were unaffected with age, indicative of sustained expression 
during normal brain aging. Finally, Akt and mTOR were detected at the cytoplasmic level, 
verifying a respectively increase or decrease immunoreactivity in neurons during brain aging, 
particularly from 60 onward. 
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Discussion 
Available evidence suggests that changes in oxidative stress homeostasis is a conserved 
mechanism of age-related functional decline [13,14,31]. Thus, previous studies have reported 
increased levels of a) protein carbonyls, comparing young adults versus aged animal groups, in 
whole brain and specific regions in rats [32–34], and in the occipital lobe of human brain tissue  
[35]; b) 8-oxodG, a marker of DNA oxidation, in rat brain [36,37], and c) the advanced glycation 
endproducts Ne-carboxymethyl-lysine (CML), imidazolone and pentosidine, all of them using 
immunohistochemistry techniques, in aged and AD human brains [38–40]. The present study is 
the first to analyze selective and specific protein oxidative damage markers by mass spectrometry 
in frontal cortex from healthy humans covering an age range of 43 to 86 years old (n=41 
individuals). Our results demonstrate that there is an increase in protein oxidative (GSA and 
AASA markers) and glycoxidative (CML and CEL markers) damage in human frontal cortex over 
the course of the adult lifespan. This increase seems to be selective because temporal trajectories 
for markers derived from the non-enzymatic modification of cysteine residues (CMC and SC) 
were maintained unchanged with age. A possible explanation for this dissociation in the behavior 
of different protein damage markers may be the cellular homeostatic mechanisms behind their 
formation. Thus, the increase in the oxidation markers could reflect an increase in the net flux of 
free radical generation, but also a decrease in the activity of protein turnover mechanisms; and for 
protein glycoxidation, the increased levels could express an increased oxidative stress status (again 
free radical generation and protein turnover), but also an increased level in the content of 
carbonyl compounds which act as a substrate for the formation of these markers which, in turn, 
reflect the concentration of carbohydrates that participate essentially in anaerobic glycolysis. In 
contrast, the unchanged content in markers derived from cysteine modification may be an 
indication of better preservation of cysteine residues and their functionality by specific repair 
mechanisms over the adult lifespan―mechanisms which are absent for other kind of markers. 
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Studies of gene expression reveal that decreased expression of mitochondrial genes is a conserved 
trait of the aging process in animal species ranging from C.elegans to humans [2,8–10,12,25]. 
Additionally, our results demonstrate a progressive loss in the content of mitochondrial electron 
transport chain (ETC) complexes from CI to CIV, and also that this decrease is effective from 
age 60 onward, concomitant with the breakpoint where the accrual of protein damage markers 
starts. Interestingly, there is a temporal gap in the progressive loss in the content of 
mitochondrial ETC complexes from CI to CIV, being evident in the decade following age 50 for 
CI, and age 60 for CII, CIII, and CIV. Inside mitochondria, electrons from reduced substrates 
move from CI and CII of the ETC through CIII and CIV to oxygen, forming water and causing 
protons to be pumped across the mitochondrial inner membrane. When glucose is metabolized 
through the TCA cycle (or fatty acids through β-oxidation), it generates electron donors. The 
main electron donor is NADH, which gives electrons to CI. The other electron donor generated 
by the TCA cycle is FADH2, formed by succinate dehydrogenase, which donates electrons to 
CII. In this context, we propose the existence of an adaptive mechanism boosted to preserve the 
decline of mitochondrial bioenergetics capacity during brain aging based on a shift in brain 
metabolic control from glucose-driven bioenergetics to a compensatory and supplementary fatty 
acid β-oxidation pathway in order to maintain neuronal function and survival. 
Consequently, the decrease in mitochondria-related gene expression and content of electron 
transport chain complexes could be on the basis of a normal decrement in mitochondrial 
function which could contribute to the age-dependent functional deficits in neurons and, in 
exacerbated cases, render neurons vulnerable to age-dependent neurodegenerative pathology. 
Another important element is to define the temporal trajectories of these physiological changes. 
A recent study showed that the transcriptional profile of the human frontal cortex from 
individuals ranging from 26 to 106 years of age defined a set of genes with reduced expression 
after age 40 [9]. In addition to this change in transcriptional profile, other studies analyzing the 
main lipid classes of different areas of human brain have also confirmed the occurrence of age-
15 
 
related lipid alterations. Globally, all the described changes are perfectly aligned to the progressive 
and deleterious character of the aging process, and it seems that concentrations of most lipids in 
the human brain decrease after the age of 50 [4]. In the present study, we demonstrate that the 
breakpoint at which the temporal trajectories for oxidative and glycoxidative markers change in 
human frontal cortex expressing a progressive increase in protein damage is at 60 years old. 
Whether the described breakpoints (transcriptional profile at 40 years old, lipid composition at 50 
years old, and protein damage at 60 years old) express a progressive and additional deleterious 
effect at molecular levels, or are independent pathways of the aging process, is a question that 
remains unanswered. But it is plausible to postulate that these changes might represent, from a 
given threshold, the molecular substrate determining a change in the normal temporal trajectory 
toward the onset of AD pathology. 
The preservation of neural cells (particularly neurons) and cognitive functions throughout an 
entire healthy adult lifespan demands a cellular adaption involving robust stress-response 
mechanisms. In this context, a recent study showed that REST (also known as neuron-restrictive 
silencer factor, NRSF) - which regulates a network of genes that mediate cell stress resistance- is 
induced in human brain during aging, being associated with preservation of cognitive function 
and increased longevity [29]. By contrast, this gene network becomes affected at early stages of 
AD when REST is lost from the nucleus [29]. Our results confirm this observation and 
demonstrate that the presence of sustained and elevated REST levels at the nuclear level is 
present over the adult lifespan of healthy humans. In addition, the correlation between REST 
content and protein oxidation reinforces the idea that stressors like oxidative stress could be the 
trigger inducing REST expression as an adaptive response.  
An additional mechanism may be mediated by the PI3-K/Akt/mTOR signaling pathway. All 
components of the PI3-K/Akt/mTOR signaling pathway are expressed in the brain at high 
levels, predominantly but not exclusively in neurons [30]. In post-mitotic neurons the integration 
of neuronal responses through this signaling pathway has significant functional effect on stress 
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responses, synaptic function, and cognitive processing, and it is involved in brain aging, and age-
related neurodegenerative diseases [41–43]. mTOR is a conserved serine/threonine kinase which 
regulates metabolism in response to different factors such as nutrients, growth factors, and 
cellular energy conditions. An increasing number of studies show that disturbance in mTOR 
signaling in the brain affects multiple pathways including glucose metabolism, energy production, 
mitochondrial function, and autophagy. All these events could be key players in age-related 
cognitive decline as well as neurodegenerative diseases. Thus, signaling through the PI3-
K/Akt/mTOR pathway and its activation is negatively affected in the brain of individuals with 
AD compared with healthy subjects [44–47]. In this line, an altered Akt subcellular location have 
been described in hippocampal and cortical neurons in the AD brain [44,48]. In addition, levels 
of mTOR signaling are also specifically increased in neurons predicted to develop neurofibrillary 
tangles [46]. Conversely, attenuation of the mTOR signal, through pharmacological and 
nutritional intervention, increases longevity and is associated with a healthy lifespan, including 
improvement in brain function [41,42]. Consequently, we infer that the lower mTOR expression 
observed in the frontal cortex with age in the present study for the first time is a physiological 
adaption aimed at preserving neuronal survival and conferring resistance to stress over the adult 
lifespan. 
Here we show that oxidative and glycoxidative damage significantly increases during human brain 
aging, with a breakpoint at 60 years old. This trajectory is coincident with a decrease in the 
content of the mitochondrial respiratory chain complex I to IV. In addition, our findings suggest 
that the deterioration in oxidative stress homeostasis during aging induces an adaptive response 
of stress resistance mechanisms based on a sustained expression of REST, and increased and 
decreased content of Akt and mTOR, respectively, over the adult lifespan in order to preserve 
neuronal function. 
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Figure 1. Relationship between age and different protein oxidative biomarkers. Graphics 
show the trend of each variable with age, analyzed by generalized additive model (GAM). 
Significance of the GAM analysis are: for GSA, R2(adj)=0.556, p<0.00001, Deviance 
explained=57.7%; for AASA, R2(adj)=0.549, p<0.00001, Deviance explained=57%; for CEL, R2 
(adj)=0.305, p<0.00028, Deviance explained=33.4%; for CML, R2(adj)=0.156, p<0.012, 
Deviance explained=18.7%; for CMC, R2 (adj)=0.053, p>0.05, Deviance explained=7.51%; and 
for 2-SC, R2(adj)=0.0393, p>0.05, Deviance explained=5.88 %.  
 
Figure 2. Representative immunoblots showing relative levels of the polypeptides 
measured corresponding to the mitochondrial respiratory complex I, II, III, IV, ATP 
synthase (Complex V), and AIF. Values are expressed as mean ± SEM from 5 different frontal 
cortex human samples normalized for porin protein levels as a mitochondrial marker. 
a significantly different from 40-49 group, b significantly different from 50-59 group, c significantly 
different from 60-69 group, d significantly different from 70-79 group. *p<0.05, **p<0.01, 
***p<0.001. 
 
Figure 3. Representative immunoblots and mRNA relative expression of REST, Akt and 
mTOR. Values are expressed as mean ± SEM from 5 different brain human samples normalized 
for actin protein levels for REST and ratios of phosphorylated mTOR to total mTOR and 
phosphorylated Akt to total-Akt. asignificantly different from 40-49 group, b significantly different 
from 50-59 group, c significantly different from 60-69 group, d significantly different from 70-79 
group. *p<0.05, **p<0.01. 
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Figure 4. Relationship between the steady-state levels of specific protein damage markers 
(GSA and AASA, µmol/mol lysine) and the repressor element 1-silencing transcription 
factor (REST, % change) expression. These regressions were determined and tested for 
significance using the mean values for each decade of age. Values used for regression equation 
(expressed as mean±SEM) are: For GSA: 2888.62±467.82 (40-49yrs), 2858.47±512.36 (50-59yrs), 
2831.7±411.66 (60-69yrs), 8492.43±910.06 (70-79yrs), 9237.66±1353.52 (80-89yrs); for AASA: 
64.54±37.68 (40-49yrs), 43.32±15.85 (50-59yrs), 40.49±13.78 (60-69yrs), 275.41±21.51 (70-
79yrs), 384.72±81.71 (80-89yrs); for REST: 1.00±0.19 (40-49yrs), 1.05±0.18 (50-59yrs), 
1.08±0.11 (60-69yrs), 1.22±0.21 (70-79yrs), 1.59±0.56 (80-89yrs). 
Figure 5. Representative images of Complex I, REST, Akt, and mTOR detection in 
human frontal cortex samples at each decade of age. Paraffin sections, slightly 
counterstained with haematoxylin. Bar = 25 μm. 
 
 
Table 1. Summary of cases examined. 
Case Gender Age 
(yrs) 
Post Mortem Delay RIN  
Values 
1 Man 43 4 h 35 min 7.3 
2 Man 43 5 h 55 min 7.5 
3 Woman 46 9 h 35 min 6.9 
4 Man 46 15 h 7.5 
5 Man 47 4 h 55 min  
6 Woman 48 4 h  
7 Woman 50 14 h 30 min  
8 Man 50 17 h 15 min  
9 Woman 52 5 h 45 min 6.6 
10 Man 52 4 h 40 min 7.1 
11 Man 53 3 h  
12 Man 53 7 h 25 min  
13 Man 56 3 h 45 min 7.1 
14 Woman 58 4 h  
15 Man 58 4 h 7.3 
16 Man 61 3 h 55 min 7.4 
17 Woman 64 5 h  
18 Man 64 8 h 35 min  
19 Man 65 16 h 6.1 
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Highlights 
 Protein oxidative and glycoxidative damage significantly increases during human brain 
aging, with a breakpoint at 60 years old.  
 This trajectory is coincident with a decrease in the content of the mitochondrial 
respiratory chain complex I to IV.  
 The deterioration in oxidative stress homeostasis during brain aging induces an adaptive 
response of stress resistance mechanisms over the adult lifespan in order to preserve 
neuronal function. 
 
 
20 Woman 66 4 h 15min 7.1 
21 Woman 67 5 h 20 min 5.8 
22 Man 68 10 h 55 min  
23 Man 70 2 h 7.3 
24 Woman 71 6 h 6.7 
25 Woman 71 8 h 30 min 6.7 
26 Man 72 3 h 35 min 7.5 
27 Woman 73 4 h 30 min  
28 Woman 73 5 h 30 min  
29 Woman 75 3 h 25 min  
30 Man 76 4 h 15 min  
31 Man 76 6 h 30 min  
32 Woman 79 3 h 35 min  
33 Woman 79 5 h  
34 Woman 81 4 h  
35 Woman 82 3 h 05 min 6.9 
36 Man 83 3 h 03 min 7 
37 Man 83 4 h 30 min 7.3 
38 Woman 86 4 h 15 min  
39 Woman 86 19 h 30 min  
40 Man 86 5 h 35 min 6 
41 Man 86 18 h  
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